Clene Inc.
- CLNN
- NASDAQ
- Biotechnology
- Nanomedicine (CSN)
- Clinical-Stage Biotech
- Neurology/ALS
$3.35
Today +7.90%Quote Oct 19, 2026, 04:09 PM UTC
−25.30%over the last month
Max drawdown −31.7%From 1-month high −31.7%3 months −45.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Clene
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies.
Where the money comes from
Q2 2026 revenue $90,000
- Product$74,00082.2%
- Royalty$16,00017.8%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
78
Market value
$43.0M
Quote Oct 19
Analyst target
$50.00
+1394.8% from here
Floor
$3.28
2.0% below price
Resistance
$3.49
4.4% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CLNNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free